Cediranib (AZD2171) in Patients with Advanced Hepatocellular Carcinoma: A Phase II North Central Cancer Treatment Group (NCCTG) Clinical Trial
      QxMD      Google Scholar   
Citation:
Am. J. Clin. Oncol. vol 35 (4) 329-333
Year:
2012
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
DataSharing:
No
Book Volume:
1
Parents:
400   404  
Children:
None
Program:
OGC
Primary Committee:
GI
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA035267, N01 CA035431, CA-37404, CA-35090, CA-35195, U10 CA037404, U10 CA035195, CA-25224, U10 CA037404-21, U10 CA035431, U10 CA025224, U10 CA035090, CA-35267, U10 CA025224-26  
Corr. Author:
 
Authors:
               
Primary Study
N044J
Secondary Studies:
Phases:
2
Keywords:
AZD2171, cediranib, hepatocellular carcinoma, phase II, VEGF